| Literature DB >> 30186264 |
Hidetada Hirakawa1, Kumiko Kurabayashi1, Koichi Tanimoto2, Haruyoshi Tomita1,2.
Abstract
Fosfomycin is resurfacing as a "last resort drug" to treat infections caused by multidrug resistant pathogens. This drug has a remarkable benefit in that its activity increases under oxygen-limited conditions unlike other commonly used antimicrobials such as β-lactams, fluoroquinolones and aminoglycosides. Especially, utility of fosfomycin has being evaluated with particular interest to treat chronic biofilm infections caused by Pseudomonas aeruginosa because it often encounters anaerobic situations. Here, we showed that P. aeruginosa PAO1, commonly used in many laboratories, becomes more susceptible to fosfomycin when grown anaerobically, and studied on how fosfomycin increases its activity under anaerobic conditions. Results of transport assay and gene expression study indicated that PAO1 cells grown anaerobically exhibit a higher expression of glpT encoding a glycerol-3-phosphate transporter which is responsible for fosfomycin uptake, then lead to increased intracellular accumulation of the drug. Elevated expression of glpT in anaerobic cultures depended on ANR, a transcriptional regulator that is activated under anaerobic conditions. Purified ANR protein bound to the DNA fragment from glpT region upstream, suggesting it is an activator of glpT gene expression. We found that increased susceptibility to fosfomycin was also observed in a clinical isolate which has a promoted biofilm phenotype and its glpT and anr genes are highly conserved with those of PAO1. We conclude that increased antibacterial activity of fosfomycin to P. aeruginosa under anaerobic conditions is attributed to elevated expression of GlpT following activation of ANR, then leads to increased uptake of the drug.Entities:
Keywords: anaerobiosis; antimicrobial resistance (AMR); cystic fibrosis; fosfomycin; multi-drug resistance (MDR)
Year: 2018 PMID: 30186264 PMCID: PMC6110920 DOI: 10.3389/fmicb.2018.01950
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Strains and plasmids used in this study.
| Strain or plasmid | Relevant genotype/phenotype | Reference |
|---|---|---|
| PAO1 | ||
| PAO1ΔglpT | This work | |
| Ps.a-682 | This work | |
| MG1655 | ||
| MC4100 | ||
| RosettaTM(DE3) | T7-expression strain, CmR | Novagen/EMD Bioscience |
| pEX18Gm | Suicide vector with a | |
| pBBR1MCS4 | Broad range host vector; ApR | |
| pBBR1MCS4lacZ | pBBR1MCS4 with promoterless | This work |
| pBBRglpT(PAO1)-P | This work | |
| pBBRglpT(Ps.a-682)-P | This work | |
| pBBRfosA(PAO1)-P | This work | |
| pBBRglpR(PAO1)-P | This work | |
| pNN387 | Single copy plasmid with promoterless | |
| pNNglpT(PAO1)-P | This work | |
| pBBR1MCS5 | Broad range host vector; GmR | |
| pBBR1MCS5glpT | GlpT expression; GmR | This work |
| pTrc99A | Vector for IPTG-inducible expression; ApR | |
| pTrc99Aanr | ANR expression in | This work |
| pQE80L | Vector for expression of His-tagged protein; ApR | Qiagen |
| pQE80anr | N-terminal His6-ANR overexpression plasmid; ApR | This work |
Primers used in this study.
| Primer | DNA sequence (5′–3′) | Use |
|---|---|---|
| glpT-PA-delta1 | gcgggatccgtcggcgtgttctggggatc | |
| glpT-PA-delta2 | gagccgccgcgtcatcagccggctccgaacatcgcgagctccg | |
| glpT-PA-delta3 | aagcggagctcgcgatgttcggagccggctgatgacgcggcgg | |
| glpT-PA-delta4 | gcgaagcttatctggcggaactgcccgac | |
| lacZ-F | gcgggtacctttcacacaggaaacagctatg | pBBR1MCS4lacZ construction |
| lacZ-R | gcctctagattatttttgacaccagaccaac | pBBR1MCS4lacZ construction |
| glpT-PA-PF-NsiI | gcgatgcatcgccctcggccagcgcagg | pBBRglpT(PAO1)-P and pBBRglpT(Ps.a-682) construction |
| glpT-PA-PR-KpnI | gcgggtaccgcgagctccgcttgttgttg | pBBRglpT(PAO1)-P and pBBRglpT(Ps.a-682) construction |
| fosA-PF | gcgatgcatatggtcgaggtcgacgtgc | pBBRfosA(PAO1)-P construction |
| fosA-PR | gcgggtaccgggggctccttgcaagatg | pBBRfosA(PAO1)-P construction |
| glpR-PF | gcgatgcatagccggagtgcgacgagcc | pBBRglpR(PAO1)-P construction |
| glpR-PF | gcgggtaccgggttgttctcgtgctgcc | pBBRglpR(PAO1)-P construction |
| glpT-PA-PF-NotI | gcggcggccgccgccctcggccagcgcagg | pNNglpT(PAO1)-P construction |
| glpT-PA-PR-HindIII | gcgaagcttgcgagctccgcttgttgttg | pNNglpT(PAO1)-P construction |
| pBBRglpT-PA-F | gcgggtaccgcgggccggagcgatacac | pBBR1MCS5glpT construction |
| pBBRglpT-PA-R | gcgaagctttcagccggcttgctgcggc | pBBR1MCS5glpT construction |
| pTrcanr-F | gcgccatggccgaaaccatcaaggtgc | pTrc99Aanr construction |
| pTrcanr-R | gcgggatcctcagccttccagctggccgc | pTrc99Aanr construction |
| pQE80anr-F | gcgggatccgccgaaaccatcaaggtgcg | pQE80anr construction |
| pQE80anr-R | gcgaagctttcagccttccagctggccg | pQE80anr construction |
| glpT-PA-PR-6FAM | tcgcgagctccgcttgttg | DNase I footprinting analyses |
| glpT-PA-RACE1 | cagccgttgatgaagagcagg | 5′-RACE analysis |
| glpT-PA-RACE2 | ggccgaacggcaggaagacc | 5′-RACE analysis |
| glpT-PA-RACE3 | tggcgatggccgacatcgcg | 5′-RACE analysis |
Fosfomycin MICs of P. aeruginosa and its derivatives.
| Strain | Fosfomycin MICs (mg/L) | |
|---|---|---|
| Aerobic | Anaerobic | |
| PAO1 | 64 | 8 |
| PAO1ΔglpT | >1024 | >1024 |
| PAO1ΔglpT/pBBR1MCS5 | >1024 | >1024 |
| PAO1ΔglpT/pBBR1MCS5glpT | 8 | 4 |
| Ps.a-682 | 64 | 16 |